194 related articles for article (PubMed ID: 8614277)
1. Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain.
Rinaldi-Carmona M; Pialot F; Congy C; Redon E; Barth F; Bachy A; Brelière JC; Soubrié P; Le Fur G
Life Sci; 1996; 58(15):1239-47. PubMed ID: 8614277
[TBL] [Abstract][Full Text] [Related]
2. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain.
Adams IB; Compton DR; Martin BR
J Pharmacol Exp Ther; 1998 Mar; 284(3):1209-17. PubMed ID: 9495885
[TBL] [Abstract][Full Text] [Related]
3. Characterization of CB1 receptors on rat neuronal cell cultures: binding and functional studies using the selective receptor antagonist SR 141716A.
Jung M; Calassi R; Rinaldi-Carmona M; Chardenot P; Le Fur G; Soubrié P; Oury-Donat F
J Neurochem; 1997 Jan; 68(1):402-9. PubMed ID: 8978752
[TBL] [Abstract][Full Text] [Related]
4. SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity.
Pan X; Ikeda SR; Lewis DL
Mol Pharmacol; 1998 Dec; 54(6):1064-72. PubMed ID: 9855635
[TBL] [Abstract][Full Text] [Related]
5. Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors.
Gatley SJ; Lan R; Pyatt B; Gifford AN; Volkow ND; Makriyannis A
Life Sci; 1997; 61(14):PL 191-7. PubMed ID: 9335234
[TBL] [Abstract][Full Text] [Related]
6. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
Janoyan JJ; Crim JL; Darmani NA
Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological properties of cannabinoid receptors in the avian brain: similarity of rat and chicken cannabinoid1 receptor recognition sites and expression of cannabinoid2 receptor-like immunoreactivity in the embryonic chick brain.
Fowler CJ; Nilsson O; Andersson M; Disney G; Jacobsson SO; Tiger G
Pharmacol Toxicol; 2001 Apr; 88(4):213-22. PubMed ID: 11322181
[TBL] [Abstract][Full Text] [Related]
8. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
Darmani NA
Neuropsychopharmacology; 2001 Feb; 24(2):198-203. PubMed ID: 11120402
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain.
Kathmann M; Bauer U; Schlicker E; Göthert M
Naunyn Schmiedebergs Arch Pharmacol; 1999 Jun; 359(6):466-70. PubMed ID: 10431757
[TBL] [Abstract][Full Text] [Related]
10. Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A.
Shire D; Calandra B; Delpech M; Dumont X; Kaghad M; Le Fur G; Caput D; Ferrara P
J Biol Chem; 1996 Mar; 271(12):6941-6. PubMed ID: 8636122
[TBL] [Abstract][Full Text] [Related]
11. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats.
Solinas M; Panlilio LV; Antoniou K; Pappas LA; Goldberg SR
J Pharmacol Exp Ther; 2003 Jul; 306(1):93-102. PubMed ID: 12660305
[TBL] [Abstract][Full Text] [Related]
12. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
McMahon LR
Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
[TBL] [Abstract][Full Text] [Related]
13. Isolation and expression of a mouse CB1 cannabinoid receptor gene. Comparison of binding properties with those of native CB1 receptors in mouse brain and N18TG2 neuroblastoma cells.
Abood ME; Ditto KE; Noel MA; Showalter VM; Tao Q
Biochem Pharmacol; 1997 Jan; 53(2):207-14. PubMed ID: 9037253
[TBL] [Abstract][Full Text] [Related]
14. The CB1 cannabinoid receptor antagonist SR 141716A affects A9 dopamine neuronal activity in the rat.
Gueudet C; Santucci V; Rinaldi-Carmona M; Soubrié P; Le Fur G
Neuroreport; 1995 Jul; 6(10):1421-5. PubMed ID: 7488739
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse.
Lay L; Angus JA; Wright CE
Eur J Pharmacol; 2000 Mar; 391(1-2):151-61. PubMed ID: 10720647
[TBL] [Abstract][Full Text] [Related]
16. SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats.
Costa B; Vailati S; Colleoni M
Behav Pharmacol; 1999 May; 10(3):327-31. PubMed ID: 10780247
[TBL] [Abstract][Full Text] [Related]
17. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors.
Gatley SJ; Gifford AN; Volkow ND; Lan R; Makriyannis A
Eur J Pharmacol; 1996 Jul; 307(3):331-8. PubMed ID: 8836622
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoid CB1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice.
Kathmann M; Weber B; Schlicker E
Naunyn Schmiedebergs Arch Pharmacol; 2001 Jan; 363(1):50-6. PubMed ID: 11191836
[TBL] [Abstract][Full Text] [Related]
19. Analogs of SR-141716A (Rimonabant) alter d-amphetamine-evoked [3H] dopamine overflow from preloaded striatal slices and amphetamine-induced hyperactivity.
Miller DK; Rodvelt KR; Constales C; Putnam WC
Life Sci; 2007 Jun; 81(1):63-71. PubMed ID: 17532007
[TBL] [Abstract][Full Text] [Related]
20. Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice.
Darmani NA; Pandya DK
J Neural Transm (Vienna); 2000; 107(8-9):931-45. PubMed ID: 11041273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
